Company Description
Davion Healthcare Plc is an Irish Public Limited Company focused exclusively on the development and commercialization of non-invasive home diagnostic tests for the early detection of health anomalies, including cancers.
Our products are classified as Class I medical devices and are fully registered with regulatory authorities in the United States (FDA), the European Union (CE mark), and the United Kingdom (UKCA).
Our flagship product, BreastCheck, is a non-invasive home test designed to detect temperature anomalies in breast tissue, which may be indicative of cancer or other health conditions.
Our broader pipeline includes a suite of non-invasive home testing kits targeting additional health indicators for early detection, prevention, and wellness monitoring.
| Country | Ireland |
| Founded | 2022 |
| IPO Date | Oct 22, 2026 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Jack Kaye |
Contact Details
Address: The Cube Building, Monahan Road Cork, T12 H1XY Ireland | |
| Phone | +353 2129330 |
| Website | davionhealthcare.com |
Stock Details
| Ticker Symbol | DAVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $12.00 |
| CIK Code | 2039072 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Sir Eric Peacock | Non-Executive Chairman |
| Jack Kaye | Chief Executive Officer |
| David Over | Chief Commercial Officer |
| Kevin Riches | Non-Executive Director |
| Susan M King | Non-Executive Director |
| Julian F Sluyters | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 20, 2026 | 424B3 | Prospectus |
| Oct 20, 2026 | 6-K | Report of foreign issuer |
| Oct 13, 2026 | 424B3 | Prospectus |
| Sep 15, 2026 | 6-K | Report of foreign issuer |
| Sep 8, 2026 | D | Notice of Exempt Offering of Securities |
| Sep 2, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 17, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 11, 2026 | SCHEDULE 13D/A | Filing |
| May 6, 2026 | 20-F/A | Filing |